StockData

LENZ Therapeutics vs Scilex

LENZ and SCLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LENZ and SCLX compare

LENZ Therapeutics is the larger company, worth 9.9 times as much as Scilex ($120M against $12.1M).

LENZ Therapeutics grew revenue faster over the last twelve months (330% versus −28.5% for Scilex).

LENZ Therapeutics keeps more of each dollar of sales as profit, with a net margin of −587% compared with −1470% at Scilex.

LENZ Therapeutics scores higher on the StockData Score (9 against 1 for Scilex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLENZSCLX
Size and price
Market cap$120M$12.1M
Share price$3.82$1.43
Change, 1 year−85.6%−92.4%
Change, 5 years−94.3%−99.6%
Beta (5Y)2.15–
Employees15234
StockData Score
Total score9 (better)1
Valuation score3 (better)1
Growth score1 (better)0
Performance score00
Health score5 (better)0
Dividend score00
Valuation
P/S5.6×0.4× (better)
P/B0.5×–
FCF yield−95.3%–
Fair value$7.83–
Margin of safety51.2%–
Growth
Revenue growth (TTM)330% (better)−28.5%
Revenue growth, 5Y average–5.1%
Profitability
Gross margin–161%
Operating margin−632% (better)−1136%
Net margin−587% (better)−1470%
FCF margin−533%–
Return on equity−59.2%–
Financial health
Debt / equity0.00–
Interest coverage–−22.2×
Current ratio13.55 (better)0.07
Altman Z-score1.67 (better)−12.74
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions110%9.8%
Held by insiders6.7%–
Insider net buying, 12 months−$8.8M (better)−$12.8M
Short interest, % of float24.1%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.